Zebrafish Head and Neck Squamous Cell Carcinoma (HNSCC) Models

Introduction

Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous group of malignancies arising from the mucosal epithelium of the oral cavity, pharynx, and larynx. It is the sixth most common cancer worldwide, with approximately 890,000 new cases and 450,000 deaths annually. Two major etiological subtypes are recognized: HPV-negative HNSCC, driven primarily by tobacco and alcohol consumption, and HPV-positive HNSCC, caused by persistent infection with high-risk HPV types—predominantly HPV16—and most commonly affecting the oropharynx. HPV-positive HNSCC has risen sharply in incidence over the past two decades, particularly in younger men in high-income countries. Common clinical presentations include non-healing oral ulcers, dysphagia, hoarseness, and cervical lymphadenopathy. Prognosis is stage- and etiology-dependent: HPV-positive tumors carry a significantly better prognosis than HPV-negative tumors, with five-year survival rates of ~75–80% versus ~40–50%, respectively.

Current treatment paradigms include surgery, radiotherapy, and platinum-based chemoradiotherapy. For recurrent/metastatic disease, immune checkpoint inhibitors (pembrolizumab) and the EGFR inhibitor cetuximab are approved. Despite these advances, therapeutic resistance, locoregional recurrence, and distant metastasis remain major clinical challenges. Preclinical models that capture the molecular heterogeneity, tumor microenvironment, and metastatic behavior of HNSCC are urgently needed. Zebrafish models offer a tractable platform for HNSCC xenograft studies, enabling real-time imaging of tumor invasion, angiogenesis, and metastatic dissemination, as well as moderate-throughput drug screening across HPV-positive and HPV-negative subtypes.

Why Zebrafish?

• Real-time Visualization: Optical transparency enables real-time visualization of tumor cell invasion, angiogenesis, and micrometastasis in living animals.
• High Fecundity: High fecundity supports moderate-to-high-throughput drug screening with statistically robust sample sizes within 3–5 days.
• Conserved Cancer Pathways: Conserved cancer pathways—EGFR, PI3K/AKT/mTOR, p53, and angiogenic signaling are functionally conserved in zebrafish.
• Minimal Compound Requirement: Minimal compound requirements facilitate early-stage PK/PD and toxicity profiling of scarce or costly candidate compounds.
• Immunocompromised Lines: Immunocompromised lines (e.g., rag2 mutants) allow engraftment of human HNSCC cell lines without immune rejection.

Available Zebrafish Disease Models

Our HNSCC xenograft panel spans HPV-negative and HPV-positive cell lines for subtype-specific research:

Phenotypic Evaluation

Key Applications

• Anti-HNSCC Drug Screening: Evaluate small molecules, biologics, and natural products across HPV-positive and HPV-negative subtypes in vivo.
• EGFR-Targeted Therapy Evaluation: Assess cetuximab, EGFR inhibitors, and combination regimens using tumor burden and angiogenesis readouts.
• Metastasis and Invasion Studies: Track tumor cell dissemination, perineural invasion-like behavior, and distant colonization in real time.
• HPV Subtype Comparison: Compare drug sensitivity, metastatic potential, and angiogenic activity between HPV16+ and HPV− HNSCC models.
• Combination Therapy and Resistance Modeling: Test cisplatin/cetuximab/immunotherapy combinations and characterize mechanisms of acquired resistance.